These vaccine targets are non-mutated melanoma-associated antigens that show high and prevalent expression in melanoma, restricted expression and distribution in non-malignant tissues, and immunogenicity, characteristics that are shared with CSPG4. This evidence concerns the gene CSPG4 and melanoma.